Influenza viral neuraminidase: the forgotten antigen

References

• La Montagne JR, Noble GR, Quinnan GV et al. Summary of clinical trials of inactivated influenza vaccine – 1978. Rev. Infect. Dis.5(4), 723–736 (1983).
   PubMedGoogle Scholar
• Quinnan GV, Schooley R, Dolin R, Ennis FA, Gross P, Gwaltney JM. Serologic responses and systemic reactions in adults after vaccination with monovalent A/USSR/77 and trivalent A/USSR/77, A/Texas/77, B/Hong Kong/72 influenza vaccines. Rev. Infect. Dis.5(4), 748–757 (1983).
   PubMedGoogle Scholar
• Frank JW. Explaining vaccine failures – the use of a sports analogy. Can. J. Pub. Health76(2), 130–132 (1985).
   PubMed Web of Science ®Google Scholar
• Madjid M, Naghavi M, Litovsky S, Casscells SW. Influenza and cardiovascular disease: a new opportunity for prevention and the need for further studies. Circulation108(22), 2730–2736 (2003).
   PubMed Web of Science ®Google Scholar
• Naghavi M, Wyde P, Litovsky S et al. Influenza infection exerts prominent inflammatory and thrombotic effects on the atherosclerotic plaques of apolipoprotein E-deficient mice. Circulation107(5), 762–768 (2003).
   PubMed Web of Science ®Google Scholar
• Mostow SR. Influenza – a preventable disease not being prevented. Am. Rev. Respir. Dis.134(1), 1 (1986).
   PubMedGoogle Scholar
• Fiore AE, Shay DK, Broder K et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm. Rep.57(RR-7), 1–60 (2008).
   PubMedGoogle Scholar
• Gani R, Hughes H, Fleming D, Griffin T, Medlock J, Leach S. Potential impact of antiviral drug use during influenza pandemic. Emerg. Infect. Dis.11(9), 1355–1362 (2005).
   PubMed Web of Science ®Google Scholar
• Kiso M, Mitamura K, Sakai-Tagawa Y et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet364(9436), 759–765 (2004).
   PubMed Web of Science ®Google Scholar
• Besselaar TG, Naidoo D, Buys A et al. Widespread oseltamivir resistance in influenza A viruses (H1N1), South Africa. Emerg. Infect. Dis.14(11), 1809–1810 (2008).
   PubMed Web of Science ®Google Scholar
• Hurt AC, Ernest J, Deng YM et al. Emergence and spread of oseltamivir-resistant A (H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res.83(1), 90–93 (2009).
   PubMed Web of Science ®Google Scholar
• Choppin PW, Murphy JS, Tamm I. Studies of two kinds of virus particles which comprise influenza A2 virus strains. III. Morphological characteristics: independence to morphological and functional traits. J. Exp. Med.112, 945–952 (1960).
   PubMed Web of Science ®Google Scholar
• Choppin PW, Tamm I. Studies of two kinds of virus particles which comprise influenza A2 virus strains. II. Reactivity with virus inhibitors in normal sera. J. Exp. Med.112, 921–944 (1960).
   PubMed Web of Science ®Google Scholar
• Gottschalk A. Neuraminidase: the specific enzyme of influenza virus and Vibrio cholerae. Biochim. Biophys. Acta23(3), 645–646 (1957).
   PubMed Web of Science ®Google Scholar
• Kilbourne ED. Influenza pandemics of the 20th century. Emerg. Infect. Dis.12(1), 9–14 (2006).
   PubMed Web of Science ®Google Scholar
• Kilbourne ED. Influenza immunity: new insights from old studies. J. Infect. Dis.193(1), 7–8 (2006).
   PubMed Web of Science ®Google Scholar
• Baum LG, Paulson JC. The N2 neuraminidase of human influenza virus has acquired a substrate specificity complementary to the hemagglutinin receptor specificity. Virology180(1), 10–15 (1991).
   PubMed Web of Science ®Google Scholar
• Xu G, Suzuki T, Maejima Y et al. Sialidase of swine influenza A viruses: variation of the recognition specificities for sialyl linkages and for the molecular species of sialic acid with the year of isolation. Glycoconj. J.12(2), 156–161 (1995).
   PubMed Web of Science ®Google Scholar
• Gambaryan AS, Matrosovich MN, Bender CA, Kilbourne ED. Differences in the biological phenotype of low-yielding (L) and high-yielding (H) variants of swine influenza virus A/NJ/11/76 are associated with their different receptor-binding activity. Virology247(2), 223–231 (1998).
   PubMed Web of Science ®Google Scholar
• Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J. Virol.78(22), 12665–12667 (2004).
   PubMed Web of Science ®Google Scholar
• Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc. Natl Acad. Sci. USA101(13), 4620–4624 (2004).
   PubMed Web of Science ®Google Scholar
• Schulman JL, Khakpour M, Kilbourne ED. Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice. J. Virol.2(8), 778–786 (1968).
   PubMed Web of Science ®Google Scholar
• Lamb RA, Choppin PW. The gene structure and replication of influenza virus. Ann. Rev. Biochem.52, 467–506 (1983).
   PubMed Web of Science ®Google Scholar
• Lamb RA, Zebedee SL, Richardson CD. Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell40(3), 627–633 (1985).
   PubMed Web of Science ®Google Scholar
• Zebedee SL, Richardson CD, Lamb RA. Characterization of the influenza virus M2 integral membrane protein and expression at the infected-cell surface from cloned cDNA. J. Virol.56(2), 502–511 (1985).
   PubMed Web of Science ®Google Scholar
• Liu W, Li H, Chen YH. N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication. FEMS Immunol. Med. Microbiol.35(2), 141–146 (2003).
   PubMedGoogle Scholar
• Black RA, Rota PA, Gorodkova N, Cramer A, Klenk HD, Kendal AP. Production of the M2 protein of influenza A virus in insect cells is enhanced in the presence of amantadine. J. Gen. Virol.74(Pt 8), 1673–1677 (1993).
   PubMed Web of Science ®Google Scholar
• Black RA, Rota PA, Gorodkova N, Klenk HD, Kendal AP. Antibody response to the M2 protein of influenza A virus expressed in insect cells. J. Gen. Virol.74(Pt 1), 143–146 (1993).
   PubMed Web of Science ®Google Scholar
• Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med.5(10), 1157–1163 (1999).
   PubMed Web of Science ®Google Scholar
• Boulo S, Akarsu H, Ruigrok RW, Baudin F. Nuclear traffic of influenza virus proteins and ribonucleoprotein complexes. Virus Res.124(1–2), 12–21 (2007).
   PubMed Web of Science ®Google Scholar
• Chen W, Calvo PA, Malide D et al. A novel influenza A virus mitochondrial protein that induces cell death. Nat. Med.7(12), 1306–1312 (2001).
   PubMed Web of Science ®Google Scholar
• Wang X, Li M, Zheng H et al. Influenza A virus NS1 protein prevents activation of NF-κB and induction of α/β interferon. J. Virol.74(24), 11566–11573 (2000).
   PubMed Web of Science ®Google Scholar
• Hobson D, Baker FA, Chivers CP, Reed SE, Sharp D. A comparison of monovalent Hong Kong influenza virus vaccine with vaccines containing only pre-1968 Asian strains in adult volunteers. A report to the Medical research council committee on influenza and other respiratory virus vaccines. J. Hyg. (Lond.)68(3), 369–378 (1970).
   PubMedGoogle Scholar
• Hobson D, Baker FA, Curry RL. Effect of influenza vaccines in stimulating antibody in volunteers with prior immunity. Lancet2(7821), 155–156 (1973).
   PubMed Web of Science ®Google Scholar
• Hobson D, Baker FA, Curry RL, Beare AS, Massey PM. The efficacy of live and inactivated vaccines of Hong Kong influenza virus in an industrial community. A report to the Medical research council committee on influenza and other respiratory virus vaccines. J. Hyg. (Lond.)71(4), 641–647 (1973).
   PubMedGoogle Scholar
• Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J. Hyg. (Lond.)70(4), 767–777 (1972).
   PubMedGoogle Scholar
• Eichelberger M, Golding H, Hess M et al. FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development. Bethesda, Maryland, US, December 10–11, 2007. Vaccine26(34), 4299–4303 (2008).
   PubMed Web of Science ®Google Scholar
• Hassantoufighi A, Zhang H, Sandbulte M et al. A practical influenza neutralization assay to simultaneously quantify hemagglutinin and neuraminidase-inhibiting antibody responses. Vaccine28(3), 790–797 (2010).
   PubMed Web of Science ®Google Scholar
• Gavrilov V, Orekov T, Alabanza C et al. Influenza virus-like particles as a new tool for vaccine immunogenicity testing: validation of a neuraminidase neutralizing antibody assay. J. Virol. Methods173(2), 364–373 (2011).
   PubMed Web of Science ®Google Scholar
• Mandler J, Scholtissek C. Localisation of the temperature-sensitive defect in the nucleoprotein of an influenza A/FPV/Rostock/34 virus. Virus Res.12(2), 113–121 (1989).
   PubMed Web of Science ®Google Scholar
• Johansson BE, Kilbourne ED. Immunization with dissociated neuraminidase, matrix, and nucleoproteins from influenza A virus eliminates cognate help and antigenic competition. Virology225(1), 136–144 (1996).
   PubMed Web of Science ®Google Scholar
• Lawson CM, Bennink JR, Restifo NP, Yewdell JW, Murphy BR. Primary pulmonary cytotoxic T lymphocytes induced by immunization with a vaccinia virus recombinant expressing influenza A virus nucleoprotein peptide do not protect mice against challenge. J. Virol.68(6), 3505–3511 (1994).
   PubMed Web of Science ®Google Scholar
• Lin YL, Askonas BA. Biological properties of an influenza A virus-specific killer T cell clone. Inhibition of virus replication in vivo and induction of delayed-type hypersensitivity reactions. J. Exp. Med.154(2), 225–234 (1981).
   PubMed Web of Science ®Google Scholar
• Mcmichael AJ, Gotch F, Cullen P, Askonas B, Webster RG. The human cytotoxic T cell response to influenza A vaccination. Clin. Exp. Immunol.43(2), 276–284 (1981).
   PubMed Web of Science ®Google Scholar
• Mcmurry JA, Johansson BE, De Groot AS. A call to cellular & humoral arms: enlisting cognate T cell help to develop broad-spectrum vaccines against influenza A. Hum. Vaccin.4(2), 148–157 (2008).
   PubMed Web of Science ®Google Scholar
• Johansson BE, Moran TM, Bona CA, Popple SW, Kilbourne ED. Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. II. Sequential infection of mice simulates human experience. J. Immunol.139(6), 2010–2014 (1987).
   PubMed Web of Science ®Google Scholar
• Johansson BE, Moran TM, Kilbourne ED. Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins. Proc. Natl Acad. Sci. USA84(19), 6869–6873 (1987).
   PubMed Web of Science ®Google Scholar
• Russell SM, Liew FY. Cell cooperation in antibody responses to influenza virus. I. priming of helper T cells by internal components of virion. Eur. J. Immunol.10(10), 791–796 (1980).
   PubMed Web of Science ®Google Scholar
• Russell SM, Liew FY. T cells primed by influenza virion internal components can cooperate in the antibody response to haemagglutinin. Nature280(5718), 147–148 (1979).
   PubMed Web of Science ®Google Scholar
• Scherle PA, Gerhard W. Functional analysis of influenza-specific helper T cell clones in vivo. T cells specific for internal viral proteins provide cognate help for B cell responses to hemagglutinin. J. Exp. Med.164(4), 1114–1128 (1986).
   PubMed Web of Science ®Google Scholar
• Ross TM, Mahmood K, Crevar CJ, Schneider-Ohrum K, Heaton PM, Bright RA. A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets. PLoS One4(6), e6032 (2009).
   PubMed Web of Science ®Google Scholar
• Bright RA, Carter DM, Daniluk S et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine25(19), 3871–3878 (2007).
   PubMed Web of Science ®Google Scholar
• Pushko P, Tumpey TM, Van Hoeven N et al. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. Vaccine25(21), 4283–4290 (2007).
   PubMed Web of Science ®Google Scholar
• Ulmer JB, Fu TM, Deck RR et al. Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA. J. Virol.72(7), 5648–5653 (1998).
   PubMed Web of Science ®Google Scholar
• Montgomery DL, Shiver JW, Leander KR et al. Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors. DNA Cell Biol.12(9), 777–783 (1993).
   PubMed Web of Science ®Google Scholar
• Bender BS, Ulmer JB, Dewitt CM et al. Immunogenicity and efficacy of DNA vaccines encoding influenza A proteins in aged mice. Vaccine16(18), 1748–1755 (1998).
   PubMed Web of Science ®Google Scholar
• Donnelly JJ, Friedman A, Martinez D et al. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat. Med.1(6), 583–587 (1995).
   PubMed Web of Science ®Google Scholar
• Donnelly JJ, Friedman A, Ulmer JB, Liu MA. Further protection against antigenic drift of influenza virus in a ferret model by DNA vaccination. Vaccine15(8), 865–868 (1997).
   PubMed Web of Science ®Google Scholar
• Ennis FA, Rook AH, Qi YH et al. HLA restricted virus-specific cytotoxic T-lymphocyte responses to live and inactivated influenza vaccines. Lancet2(8252), 887–891 (1981).
   PubMed Web of Science ®Google Scholar
• Doherty PC, Turner SJ, Webby RG, Thomas PG. Influenza and the challenge for immunology. Nat. Immunol.7(5), 449–455 (2006).
   PubMed Web of Science ®Google Scholar
• Wise TG, Dolin R, Mazur MH, Ennis FA. Serologic responses after two sequential doses of influenza A/New Jersey/76 virus vaccine in normal young adults. J. Infect. Dis.136(Suppl.), S496–S499 (1977).
   Google Scholar
• Gross PA. Reactogenicity and immunogenicity of bivalent influenza vaccine in one- and two-dose trials in children: a summary. J. Infect. Dis.136(Suppl.), S616–S625 (1977).
   PubMedGoogle Scholar
• Johansson BE, Brett IC. Changing perspective on immunization against influenza. Vaccine25(16), 3062–3065 (2007).
   PubMed Web of Science ®Google Scholar
• Belshe RB. A review of attenuation of influenza viruses by genetic manipulation. Am. J. Respir. Crit. Care Med.152(4 Pt 2), S72–S75 (1995).
   Google Scholar
• Kilbourne ED. An explanation of the interpandemic antigenic mutability of influenza viruses. J. Infect. Dis.128(5), 668–670 (1973).
   PubMed Web of Science ®Google Scholar
• Kilbourne ED. The molecular epidemiology of influenza. J. Infect. Dis.127(4), 478–487 (1973).
   PubMed Web of Science ®Google Scholar
• CDC. Prevention and control of influenza : recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep.53(RR06), 1–40 (2004).
   PubMedGoogle Scholar
• Besselaar TG, Blackburn NK, Schoub BD. The molecular characterization of influenza virus strains isolated in South Africa during 1993 and 1994. Res. Virol.147(4), 239–245 (1996).
   PubMedGoogle Scholar
• Besselaar TG, Botha L, Mcanerney JM, Schoub BD. Antigenic and molecular analysis of influenza A (H3N2) virus strains isolated from a localised influenza outbreak in South Africa in 2003. J. Med. Virol.73(1), 71–78 (2004).
   PubMed Web of Science ®Google Scholar
• Wise TG, Dolin R, Mazur MH, Top FH Jr, Edelman R, Ennis FA. Serologic responses and systemic reactions in adults after vaccination with bivalent A/Victoria/75-A/New Jersey/76 and monovalent B/Hong Kong/72 influenza vaccines. J. Infect. Dis.136(Suppl.), S507–S517 (1977).
   Google Scholar
• Ennis FA, Wise TG, Mclaren C, Verbonitz MW. Serological responses to whole and split A/New Jersey vaccines in humans and mice following priming infection with influenza A viruses. Dev. Biol. Stand.39, 261–266 (1977).
   PubMedGoogle Scholar
• Mclaren C, Verbonitz MW, Daniel S, Grubbs GE, Ennis FA. Effect of priming infection on serologic response to whole and subunit influenza virus vaccines in animals. J. Infect. Dis.136(Suppl.), S706–S711 (1977).
   PubMed Web of Science ®Google Scholar
• Gross PA, Ennis FA. Influenza vaccine: split-product versus whole-virus types – how do they differ. N. Engl. J. Med.296(10), 567–568 (1977).
   PubMed Web of Science ®Google Scholar
• Gross PA, Ennis FA, Gaerlan PF, Denson LJ, Denning CR, Schiffman D. A controlled double-blind comparison of reactogenicity, immunogenicity, and protective efficacy of whole-virus and split-product influenza vaccines in children. J. Infect. Dis.136(5), 623–632 (1977).
   PubMed Web of Science ®Google Scholar
• Hoskins TW, Davies JR, Smith AJ, Miller CL, Allchin A. Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ’s Hospital. Lancet1(8106), 33–35 (1979).
   PubMed Web of Science ®Google Scholar
• Gerentes L, Kessler N, Aymard M. Difficulties in standardizing the neuraminidase content of influenza vaccines. Dev. Biol. Stand.98, 189–196; discussion 197 (1999).
   PubMedGoogle Scholar
• Tanimoto T, Nakatsu R, Fuke I et al. Estimation of the neuraminidase content of influenza viruses and split-product vaccines by immunochromatography. Vaccine23(37), 4598–4609 (2005).
   PubMed Web of Science ®Google Scholar
• Aymard M. Quantification of neuramidase (NA) protein content. Vaccine20(Suppl. 2), S59–S60 (2002).
   Web of Science ®Google Scholar
• Gravela C, Lib C, Wang J, Hashema A et al. Qualitative and quantitative analyses all subtypes of influenza A and B viral neuraminidases using antibodies targeting the universally conserved sequences. Vaccine28(36), 5774–5784 (2010).
   PubMed Web of Science ®Google Scholar
• Valette M, Aymard M. Quality control assessment of influenza and RSV testing in Europe: 2000–01 season. Euro. Surveill.7(11), 161–165 (2002).
   PubMedGoogle Scholar
• Kilbourne ED, Couch RB, Kasel JA et al. Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans. Vaccine13(18), 1799–1803 (1995).
   PubMed Web of Science ®Google Scholar
• Kilbourne ED, Cerini CP, Khan MW, Mitchell JW Jr, Ogra PL. Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees. J. Immunol.138(9), 3010–3013 (1987).
   PubMed Web of Science ®Google Scholar
• Kilbourne ED. Comparative efficacy of neuraminidase-specific and conventional influenza virus vaccines in induction of antibody to neuraminidase in humans. J. Infect. Dis.134(4), 384–394 (1976).
   PubMed Web of Science ®Google Scholar
• Kendal AP, Noble GR, Dowdle WR. Neuraminidase content of influenza vaccines and neuraminidase antibody responses after vaccination of immunologically primed and unprimed populations. J. Infect. Dis.136(Suppl.), S415–S424 (1977).
   Google Scholar
• Johansson BE, Brett IC. Recombinant influenza B virus HA and NA antigens administered in equivalent amounts are immunogenically equivalent and induce equivalent homotypic and broader heterovariant protection in mice than conventional and live influenza vaccines. Hum. Vaccin.4(6), 420–424 (2008).
   PubMed Web of Science ®Google Scholar
• Johansson BE, Bucher DJ, Kilbourne ED. Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J. Virol.63(3), 1239–1246 (1989).
   PubMed Web of Science ®Google Scholar
• Kilbourne ED, Christenson WN, Sande M. Antibody response in man to influenza virus neuraminidase following influenza. J. Virol.2(7), 761–762 (1968).
   PubMed Web of Science ®Google Scholar
• Kilbourne ED, Laver WG, Schulman JL, Webster RG. Antiviral activity of antiserum specific for an influenza virus neuraminidase. J. Virol.2(4), 281–288 (1968).
   PubMed Web of Science ®Google Scholar
• Bucher D, Palese P. The biologically active proteins of influenza virus: neuraminidase. In: The Influenza Viruses and Influenza. Kilbourne ED (Ed.). Academic Press, NY, USA, 83–123 (1975).
   Google Scholar
• Air GM, Laver WG. The neuraminidase of influenza virus. Proteins6, 341–356 (1989).
   PubMed Web of Science ®Google Scholar
• Huang RT, Rott R, Wahn K, Klenk HD, Kohama T. The function of the neuraminidase in membrane fusion induced by myxoviruses. Virology107(2), 313–319 (1980).
   PubMed Web of Science ®Google Scholar
• Huang RT, Wahn K, Klenk HD, Rott R. Fusion between cell membrane and liposomes containing the glycoproteins of influenza virus. Virology104(2), 294–302 (1980).
   PubMed Web of Science ®Google Scholar
• Brett IC, Johansson BE. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system. Virology339(2), 273–280 (2005).
   PubMed Web of Science ®Google Scholar
• Couch RB, Kasel JA, Gerin JL, Schulman JL, Kilbourne ED. Induction of partial immunity to influenza by a neuraminidase-specific vaccine. J. Infect. Dis.129(4), 411–420 (1974).
   PubMed Web of Science ®Google Scholar
• Johansson BE, Grajower B, Kilbourne ED. Infection-permissive immunization with influenza virus neuraminidase prevents weight loss in infected mice. Vaccine11(10), 1037–1039 (1993).
   PubMed Web of Science ®Google Scholar
• Johansson BE, Kilbourne ED. Immunization with purified N1 and N2 influenza virus neuraminidases demonstrates cross-reactivity without antigenic competition. Proc. Natl Acad. Sci. USA91(6), 2358–2361 (1994).
   PubMed Web of Science ®Google Scholar
• Johansson BE, Kilbourne ED. Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition. J. Virol.67(10), 5721–5723 (1993).
   PubMed Web of Science ®Google Scholar
• Couch RB, Douglas RG Jr, Fedson DS, Kasel JA. Correlated studies of a recombinant influenza-virus vaccine. 3. Protection against experimental influenza in man. J. Infect. Dis.124(5), 473–480 (1971).
   PubMed Web of Science ®Google Scholar
• Hocart M, Grajower B, Donabedian A, Pokorny B, Whitaker C, Kilbourne ED. Preparation and characterization of a purified influenza virus neuraminidase vaccine. Vaccine13(18), 1793–1798 (1995).
   PubMed Web of Science ®Google Scholar
• Schiff GKE, Smith G, Hackett C, Manoff S, Matthews J, Johansson B. Phase 2 clinical evaluation of an influenza A virus recombinant N2 neuraminidase vaccine. Presented at: The First European Influenza Congress, Hersonessos. Crete, Greece, 23–28 September 2000.
   Google Scholar
• Martinet W, Saelens X, Deroo T et al. Protection of mice against a lethal influenza challenge by immunization with yeast-derived recombinant influenza neuraminidase. Eur. J. Biochem.247(1), 332–338 (1997).
   PubMedGoogle Scholar
• Bosch BJ, Bodewes R, De Vries RP et al. Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets. J. Virol.84(19), 10366–10374 (2010).
   PubMed Web of Science ®Google Scholar
• Chen Z, Matsuo K, Asanuma H et al. Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs. Vaccine17(7–8), 653–659 (1999).
   PubMed Web of Science ®Google Scholar
• Chen Z, Kadowaki S, Hagiwara Y et al. Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase. Vaccine18(28), 3214–3222 (2000).
   PubMed Web of Science ®Google Scholar
• Rott R, Becht H, Orlich M. The significance of influenza virus neuraminidase in immunity. J. Gen. Virol.22(1), 35–41 (1974).
   PubMed Web of Science ®Google Scholar
• Gallagher M, Bucher DJ, Dourmashkin R, Davis JF, Rosenn G, Kilbourne ED. Isolation of immunogenic neuraminidases of human influenza viruses by a combination of genetic and biochemical procedures. J. Clin. Microbiol.20(1), 89–93 (1984).
   PubMed Web of Science ®Google Scholar
• Johansson BE, Matthews JT, Kilbourne ED. Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response. Vaccine16(9–10), 1009–1015 (1998).
   PubMed Web of Science ®Google Scholar
• Johansson BE, Pokorny BA, Tiso VA. Supplementation of conventional trivalent influenza vaccine with purified viral N1 and N2 neuraminidases induces a balanced immune response without antigenic competition. Vaccine20(11–12), 1670–1674 (2002).
   PubMed Web of Science ®Google Scholar
• Chen J, Fang F, Li X, Chang H, Chen Z. Protection against influenza virus infection in BALB/c mice immunized with a single dose of neuraminidase-expressing DNAs by electroporation. Vaccine23(34), 4322–4328 (2005).
   PubMed Web of Science ®Google Scholar
• Eickhoff TC, Meiklejohn G. Protection against Hong Kong influneza by adjuvant vaccine containing A2-Ann Arbor-67. Bull. World Health Organ.41(3), 562–563 (1969).
   PubMed Web of Science ®Google Scholar
• Monto AS, Kendal AP. Effect of neuraminidase antibody on Hong Kong influenza. Lancet1(7804), 623–625 (1973).
   PubMed Web of Science ®Google Scholar
• Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, Webby RJ. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med.4(2), e59 (2007).
   PubMed Web of Science ®Google Scholar
• Lee JT, Air GM. Interaction between a 1998 human influenza virus N2 neuraminidase and monoclonal antibody Mem5. Virology345(2), 424–433 (2006).
   PubMed Web of Science ®Google Scholar
• Lee YJ, Sung HW, Choi JG et al. Effects of homologous and heterologous neuraminidase vaccines in chickens against H5N1 highly pathogenic avian influenza. Avian. Dis.51(Suppl. 1), S476–S478 (2007).
   PubMed Web of Science ®Google Scholar
• Beutner KR, Chow T, Rubi E, Strussenberg J, Clement J, Ogra PL. Evaluation of a neuraminidase-specific influenza A virus vaccine in children: antibody responses and effects on two successive outbreaks of natural infection. J. Infect. Dis.140(6), 844–850 (1979).
   PubMed Web of Science ®Google Scholar
• Johansson BE, Moran TM, Bona CA, Kilbourne ED. Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. III. Reduced generation of neuraminidase-specific helper T cells in hemagglutinin-primed mice. J. Immunol.139(6), 2015–2019 (1987).
   PubMed Web of Science ®Google Scholar
• Johansson BE. Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine. Vaccine17(15–16), 2073–2080 (1999).
   PubMed Web of Science ®Google Scholar
• Kilbourne ED. Influenza: viral determinants of the pathogenicity and epidemicity of an invariant disease of variable occurrence. Philos. Trans. R. Soc. Lond. B. Biol. Sci.288(1029), 291–297 (1980).
   PubMed Web of Science ®Google Scholar
• Powers DC, Smith GE, Anderson EL et al. Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. J. Infect. Dis.171(6), 1595–1599 (1995).
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med.354(13), 1343–1351 (2006).
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Wilkinson BE, Masseoud F et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine19(13–14), 1732–1737 (2001).
   PubMed Web of Science ®Google Scholar
• Price GE, Soboleski MR, Lo CY et al. Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine27(47), 6512–6521 (2009).
   PubMed Web of Science ®Google Scholar
• Kilbourne ED, Johansson BE, Grajower B. Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins. Proc. Natl Acad. Sci. USA87(2), 786–790 (1990).
   PubMed Web of Science ®Google Scholar
• Johansson BE, Kilbourne ED. Comparative long-term effects in a mouse model system of influenza whole virus and purified neuraminidase vaccines followed by sequential infections. J. Infect. Dis.162(4), 800–809 (1990).
   PubMed Web of Science ®Google Scholar
• Nayak B, Kumar S, Dinapoli JM et al. Contributions of the avian influenza virus HA, NA, and M2 surface proteins to the induction of neutralizing antibodies and protective immunity. J. Virol.84(5), 2408–2420 (2010).
   PubMed Web of Science ®Google Scholar
• Buonagurio DA, Nakada S, Parvin JD, Krystal M, Palese P, Fitch WM. Evolution of human influenza A viruses over 50 years: rapid, uniform rate of change in NS gene. Science232(4753), 980–982 (1986).
   PubMed Web of Science ®Google Scholar
• Parvin JD, Moscona A, Pan WT, Leider JM, Palese P. Measurement of the mutation rates of animal viruses: influenza A virus and poliovirus type 1. J. Virol.59(2), 377–383 (1986).
   PubMed Web of Science ®Google Scholar
• Air GM, Laver WG, Webster RG, Els MC, Luo M. Antibody recognition of the influenza virus neuraminidase. Cold Spring Harb. Symp. Quant. Biol.54(Pt 1), 247–255 (1989).
   PubMedGoogle Scholar
• Cate TR, Rayford Y, Nino D et al. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine28(9), 2076–2079 (2010).
   PubMed Web of Science ®Google Scholar
• Govorkova EA, Fang HB, Tan M, Webster RG. Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob. Agents Chemother.48(12), 4855–4863 (2004).
   PubMed Web of Science ®Google Scholar
• Govorkova EA, Ilyushina NA, Mcclaren JL, Naipospos TS, Douangngeun B, Webster RG. Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. Antimicrob. Agents Chemother.53(7), 3088–3096 (2009).
   PubMed Web of Science ®Google Scholar
• Gubareva LV, Bethell R, Hart GJ, Murti KG, Penn CR, Webster RG. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J. Virol.70(3), 1818–1827 (1996).
   PubMed Web of Science ®Google Scholar
• Duan S, Boltz DA, Seiler P et al. Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets. PLoS Pathog.6(7), e1001022 (2010).
   Google Scholar
• Yen HL, Herlocher LM, Hoffmann E et al. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob. Agents Chemother.49(10), 4075–4084 (2005).
   PubMed Web of Science ®Google Scholar
• Carr J, Ives J, Kelly L et al. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res.54(2), 79–88 (2002).
   PubMed Web of Science ®Google Scholar
• Colman PM, Laver WG, Varghese JN et al. Three-dimensional structure of a complex of antibody with influenza virus neuraminidase. Nature326(6111), 358–363 (1987).
   PubMed Web of Science ®Google Scholar
• Colman PM, Tulip WR, Varghese JN et al. Three-dimensional structures of influenza virus neuraminidase-antibody complexes. Philos. Trans. R. Soc. Lond. B. Biol. Sci.323(1217), 511–518 (1989).
   PubMed Web of Science ®Google Scholar
• Hensley SE, Das SR, Gibbs JS et al. Influenza A virus hemagglutinin antibody escape promotes neuraminidase antigenic variation and drug resistance. PLoS One6(2), e15190 (2011).
   PubMed Web of Science ®Google Scholar
• Price PM, Reichelderfer CF, Johansson BE, Kilbourne ED, Acs G. Complementation of recombinant baculoviruses by coinfection with wild-type virus facilitates production in insect larvae of antigenic proteins of hepatitis B virus and influenza virus. Proc. Natl Acad. Sci. USA86(5), 1453–1456 (1989).
   PubMed Web of Science ®Google Scholar
• Hervas-Stubbs S, Rueda P, Lopez L, Leclerc C. Insect baculoviruses strongly potentiate adaptive immune responses by inducing type 1 IFN. J. Immunol.178(4), 2361–2369 (2007).
   PubMed Web of Science ®Google Scholar
• Sultana I, Gao J, Markoff L, Eichelberger MC. Influenza neuraminidase-inhibiting antibodies are induced in the presence of zanamivir. Vaccine29(14), 2601–2606 (2011).
   PubMed Web of Science ®Google Scholar
• Varghese JN, Laver WG, Colman PM. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution. Nature303(5912), 35–40 (1983).
   PubMed Web of Science ®Google Scholar
• Varghese JN, Mckimm-Breschkin JL, Caldwell JB, Kortt AA, Colman PM. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins14(3), 327–332 (1992).
   PubMed Web of Science ®Google Scholar
• Colman PM, Varghese JN, Laver WG. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature303(5912), 41–44 (1983).
   PubMed Web of Science ®Google Scholar
• Colman PM, Ward CW. Structure and diversity of influenza virus neuraminidase. Curr. Top. Microbiol. Immunol.114, 177–255 (1985).
   PubMed Web of Science ®Google Scholar
• Colman PM. Influenza virus neuraminidase: structure, antibodies, and inhibitors. Protein Sci.3(10), 1687–1696 (1994).
   PubMed Web of Science ®Google Scholar
• Dimmock NJ. Dependence of the activity of an influenza virus neuraminidase upon Ca2+. J. Gen. Virol.13(3), 481–483 (1971).
   PubMed Web of Science ®Google Scholar
• Wilson VW Jr, Rafelson MR Jr. Studies on the neuraminidases of influenza virus. 3. Stimulation of activity by bivalent cations. Biochim. Biophys. Acta146(1), 160–166 (1967).
   PubMedGoogle Scholar
• Rafelson ME Jr, Schneir M, Wilson VW Jr. Studies on the neuraminidase of influenza virus. II. Additional properties of the enzymes from the Asian and Pr 8 strains. Arch. Biochem. Biophys.103, 424–430 (1963).
   PubMed Web of Science ®Google Scholar
• Carroll SM, Paulson JC. Complete metal ion requirement of influenza virus N1 neuraminidases. Brief report. Arch. Virol.71(3), 273–277 (1982).
   PubMed Web of Science ®Google Scholar
• Johansson BE, Brett IC. Variation in the divalent cation requirements of influenza a virus N2 neuraminidases. J. Biochem.134(3), 345–352 (2003).
   PubMed Web of Science ®Google Scholar
• Brett IC, Johansson BE. Variation in the divalent cation requirements of influenza A virus N1 neuraminidases. J. Biochem.139(3), 439–447 (2006).
   PubMed Web of Science ®Google Scholar
• Sylte MJ, Suarez DL. Influenza neuraminidase as a vaccine antigen. Curr. Top. Microbiol. Immunol.333, 227–241 (2009).
   PubMedGoogle Scholar
• Colman PM. Structural basis of antigenic variation: studies of influenza virus neuraminidase. Immunol. Cell Biol.70(Pt 3), 209–214 (1992).
   PubMed Web of Science ®Google Scholar
• Colman PM. Structure of antibody-antigen complexes: implications for immune recognition. Adv. Immunol.43, 99–132 (1988).
   PubMed Web of Science ®Google Scholar
• Sylte MJ, Hubby B, Suarez DL. Influenza neuraminidase antibodies provide partial protection for chickens against high pathogenic avian influenza infection. Vaccine25(19), 3763–3772 (2007).
   PubMed Web of Science ®Google Scholar